Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Acute Agitation and Aggression Treatment Market to Reach a Value of US$ 4.4 Bn by 2027: By TMR

Transparency Market Research (TMR) has published a new report on the Acute Agitation and Aggression Treatment Market for the forecast period of 2019–2027. According to the report, the global Acute Agitation and Aggression Treatment Market was valued at ~ US$ 2.9 Bn in 2018, and is projected to expand at a CAGR of ~ 5% from 2019 to 2027. Increase in the diagnosis of agitation and aggression in psychological illnesses, establishment of organizations to spread awareness, and rise in economic burden of psychological illness contribute to the growth of the global acute agitation and aggression treatment market. 

 

acute agitation and aggression treatment market segmentation


Download a PDF Sample of Acute Agitation and Aggression Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72345 

Spreading Awareness about Agitation & Aggression and Rise in Economic Burden of Psychological Illness Drive Market 

Changing attitudes toward the diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments boost the growth of the global acute agitation and aggression treatment market. The global acute agitation and aggression treatment market is expected to expand at a CAGR of ~ 5% from 2019 to 2027.

A number of trends have been observed in the global acute agitation and aggression treatment market. Increase in the incidences of dementia among the geriatric population, rise in burden of mental illness, surge in agitation in patients, and increase in prescriptions of anti-psychotics are likely to contribute to the growth of the acute agitation and aggression treatment market.

Focus on research and development for the development of novel treatments for agitation and significant unmet clinical needs are likely to drive the global acute agitation and aggression treatment market. There is significant focus on research on the usage of combination drugs, which include a combination of anti-psychotic drugs and antidepressants.

Get A PDF Brochure fo Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=72345 

However, the social stigma associated with mental illness and preference for non-pharmacological interventions are likely to hamper the growth of the global acute agitation and aggression treatment market. 

Second-generation Anti-psychotics to Capture Major Market Share 

The acute agitation and aggression treatment market has been segmented based on drug class, route of administration, indication, end user, and region. In terms of drug class, the global acute agitation and aggression treatment market has been categorized into first-generation anti-psychotics, second-generation anti-psychotics, benzodiazepines, and others.

Based on indication, the global acute agitation and aggression treatment market has been classified into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. In terms of end user, the acute agitation and aggression treatment market has been divided into hospitals and ambulatory surgical centers, psychiatric care facilities, and others.

In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

Get Discount on Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=72345 

Significant Pipeline of Market Players to Drive Market

The report provides profiles of the leading players operating in the global acute agitation and aggression treatment market. These include Eli Lilly and Company, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Otsuka Holdings Co., Ltd., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), and H. Lundbeck A/S.

Lundbeck A/S is a global pharmaceutical company that engages in the research, development, production, marketing, and sale of pharmaceuticals across the globe. The company operates primarily in neurological and psychiatric disorders treatment. It focuses on new product launches and approvals in new markets. For instance, in July 2017, it launched Abilify Maintena in Canada for bipolar disorder. In June 2017, the company’s product Azilect received approval for Parkinson’s disease in China.

Otsuka Holdings Co., Ltd. is a global healthcare company that operates in a wide range of businesses that help in the prevention and treatment of diseases. The company operates through four segments: pharmaceuticals, nutrition, consumer products, and others. In July 2017, Otsuka Holdings Co., Ltd. announced the approval of Abilify Maintena for the additional indication of bipolar disorder in the U.S. The company’s OPC-34712 is in phase III clinical trials for the treatment of agitation associated with dementia of the Alzheimer’s type.

Order Now, Acute Agitation and Aggression Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=72345&ltype=S

Significant pipeline and focus on research and development are the key strategies employed by leading players to enhance their market presence. This is anticipated to fuel the growth of the global acute agitation and aggression treatment market. 

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Browse our Blogs for More Research Insights:

https://beetribune.com/https://bitgmx.com/https://newsregal.com

Tags: Acute Agitation and Aggression Treatment Market, Acute Agitation and Aggression Treatment Market Share, Acute Agitation and Aggression Treatment Market Size, Global Acute Agitation and Aggression Treatment Market

See Campaign: https://www.transparencymarketresearch.com/pressrelease/acute-agitation-and-aggression-treatment-mar
Contact Information:
Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: https://www.transparencymarketresearch.com

Tags:
, Research Newswire, English

image


This post first appeared on ICrowdNewswire -, please read the originial post: here

Share the post

Acute Agitation and Aggression Treatment Market to Reach a Value of US$ 4.4 Bn by 2027: By TMR

×

Subscribe to Icrowdnewswire -

Get updates delivered right to your inbox!

Thank you for your subscription

×